Tamtam Try Tamtam free
Valneva logo

Valneva account plan

Specialty vaccine development and commercialization

At a glance

Valneva is a Lyon-based specialty vaccine company with three travel vaccines, FY2025 revenues of €174.7 million and a Lyme vaccine partnered with Pfizer.

Valneva SE develops, manufactures and sells prophylactic vaccines for infectious diseases. Its three proprietary travel vaccines, IXIARO/JESPECT (Japanese encephalitis), DUKORAL (cholera / LT-ETEC) and IXCHIQ (chikungunya), serve travelers and government and military personnel, with the U.S. Department of Defense as its single largest customer. In FY2025 it reported revenues of €174.7 million, an operating loss of €82.1 million and a net loss of €115.2 million, with 674 employees at year-end (around 620 at June 30, 2026). It manufactures in Livingston (Scotland) and Solna (Sweden), runs quality and R&D in Vienna, and is listed on Euronext Paris and the Nasdaq Global Select Market; Pfizer holds 5.51% of the shares.

Business units

Strategic priorities

Lyme vaccine filings with Pfizer
The Phase 3 VALOR results announced in March 2026 showed more than 70% efficacy but missed the first pre-specified statistical criterion; Pfizer is engaging with regulators. Valneva is eligible for 14%-22% royalties, up to $100 million of sales milestones and $143 million of early commercialization milestones.
Grow and protect the travel vaccines
Maintain the trajectory of IXIARO and DUKORAL through access and awareness strategies aimed at travelers and health professionals, and generate as much cash as possible from the commercial business to fund R&D.
Refocus IXCHIQ on endemic markets
Valneva is evaluating a potential focus on endemic markets for IXCHIQ; Brazil's pilot vaccination campaign with Instituto Butantan targets 20% to 40% coverage of adults aged 18-59, and about 50,000 adults had been vaccinated by the H1 2026 report.
Shigella and enteric vaccines
Phase 2 results for the S4V2 Shigella vaccine were expected in Q3 2026, after which Valneva decides whether to take over late-stage development; it is also working on an ETEC candidate toward combination enteric vaccines.
Stringent cost management
The May 2026 restructuring reduces the global workforce by 10-15% and targets an operating expense cut of about 25-35% versus 2025, with most savings in R&D.

Latest results

In the first half of 2026 (six months to June 30), IXIARO sales fell to €44.0 million from €54.7 million, DUKORAL to €14.7 million from €17.4 million and IXCHIQ to €4.4 million from €7.5 million, while third-party sales dropped 91.6% to €1.0 million. The operating loss widened to €49.9 million (H1 2025: €16.8 million) and the net loss to €63.3 million (€20.8 million), after €9.7 million of IXCHIQ manufacturing cancellation fees and €3.2 million of restructuring expenses. Cash and cash equivalents rose to €121.5 million from €109.7 million at end-2025, helped by €34.3 million of net proceeds from the Q2 capital raise. In May 2026, citing adverse travel trends driven by geopolitical factors, the company adjusted its guidance to product sales of 135 to 150 million euros and total revenues of 145 to 160 million euros.

Investments and deals

Pharmakon debt facility
In October 2025 Valneva signed a non-dilutive facility of up to $500 million with funds managed by Pharmakon Advisors; the initial $215 million tranche repaid the previous loan, and maturity moved to Q4 2030.
April 2026 reserved offering
An up to €84 million offering of shares and warrants (€37 million at closing, up to €47 million more on warrant exercise), led by Frazier Life Sciences.
Manufacturing transfer to Almeida
IXIARO and IXCHIQ production is being transferred from the Manson site to the newer Almeida facility in Livingston, Scotland; capital expenditure fell to €2.7 million in 2025 from €17.2 million after the Scottish and Swedish investments.
Footprint consolidation in France
The Nantes site is closing, with French operations concentrated in Lyon; Nantes Métropole intends to acquire the Saint-Herblain site for €6.2 million, expected to close in September 2026.

Challenges and risks

Weaker travel demand
Management reported a reduced level of travel into geographies important for its travel vaccines, driven by geopolitical factors, which led to the May 2026 guidance cut.
IXCHIQ safety and regulatory setbacks
The U.S. license was suspended in August 2025 and the BLA withdrawn in January 2026; the end of the Serum Institute of India agreement means Valneva must find new partners for Asia.
Manufacturing and quality
Valneva received FDA Form 483 observations at Livingston and Vienna and a complete response letter on the IXIARO supplement for Almeida, and reported supply constraints for all three products in H1 2026.
Dependence on Pfizer and financing
Pfizer has sole discretion over Lyme regulatory submissions and commercialization, and the company has not achieved profitability, with ongoing funding needs and Pharmakon loan constraints.

What leadership says

“We need to maintain our existing travel vaccination offering, deliver on our financial projections and advance other programs in a diligent way”

Thomas Lingelbach, President & Chief Executive Officer · Leading Forward: Key Takeaways from 2025 and Priorities for 2026, valneva.com, January 21, 2026

“the vast majority of global vaccine revenue now sits in four to five Big Pharma companies.”

Thomas Lingelbach, President & Chief Executive Officer · Leading Forward: Key Takeaways from 2025 and Priorities for 2026, valneva.com, January 21, 2026

“the first pre-specified statistical criterion was not met, but the second one was met.”

Thomas Lingelbach, President & Chief Executive Officer · Q1 2026 earnings conference call, May 13, 2026

“to generate as much cash with the commercial business as possible.”

Thomas Lingelbach, President & Chief Executive Officer · Q1 2026 earnings conference call, May 13, 2026, on the post-Lyme strategy

Where a supplier can help

Cost-reduction partners
The restructuring targets an operating expense cut of about 25-35% versus 2025; suppliers that lower operating cost without adding headcount fit the cost-management priority.
Manufacturing quality and compliance support
Form 483 observations, a complete response letter on Almeida and failed batches make GMP quality, batch release and supply-planning help relevant to the manufacturing challenge.
Market access in endemic countries
The IXCHIQ refocus on endemic markets and the need for new Asian partners create demand for distribution, regulatory and local manufacturing partners.
Travel-vaccine demand generation
With weaker travel demand and a new German distributor, access and awareness programs aimed at travelers and health professionals support the priority of growing IXIARO and DUKORAL.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Valneva?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Valneva

What does Valneva do?

Valneva is a specialty vaccine company that develops, manufactures and sells prophylactic vaccines for infectious diseases. It markets three travel vaccines, IXIARO/JESPECT, DUKORAL and IXCHIQ, and is developing a Lyme disease vaccine with Pfizer.

What was Valneva's revenue in 2025?

FY2025 revenues were €174.7 million, of which €157.9 million of product sales, with an operating loss of €82.1 million and a net loss of €115.2 million.

How many employees does Valneva have?

Valneva had 674 employees at December 31, 2025 and around 620 at June 30, 2026, and its May 2026 restructuring reduces the global workforce by 10-15%.

Who leads Valneva?

Thomas Lingelbach has been President & CEO since 2013 and was reappointed for three years in June 2026; Peter Bühler is CFO and Gerd Zettlmeissl chairs the Board.

What is Valneva's strategy?

Valneva aims to secure filings for its Lyme vaccine with Pfizer, grow its travel vaccines, advance its Shigella and enteric programs, and keep stringent cost management.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)